Iovance Biotherapeutics (IOVA) Tax Provisions (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Tax Provisions of -$700000.0 for Q1 2026, up 61.92% year-over-year from -$432325.3 in Q1 2025, and up 99.13% quarter-over-quarter from -$80.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Tax Provisions (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Tax Provisions for 4 consecutive years, with -$700000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions rose 61.92% year-over-year to -$700000.0; the TTM figure through Mar 2026 stood at -$81.3 million (down 2412.23% YoY), while the FY2025 annual figure was -$82.5 million, down 2847.89% from the prior year.
- Tax Provisions improved to -$700000.0 in Q1 2026 per IOVA's latest filing, from -$80.2 million in the prior quarter.
- Across five years, Tax Provisions topped out at $2.0 million in Q2 2025 and bottomed at -$80.2 million in Q4 2025.
- Historically, Tax Provisions has averaged -$7.5 million across 4 years, with a median of -$1.5 million in 2024.
- On a YoY basis, Tax Provisions climbed as much as 233.33% in 2025 and fell as far as 5115.06% in 2025.
- Iovance Biotherapeutics' Tax Provisions stood at -$1.8 million in 2023, then surged by 188.89% to $1.6 million in 2024, then plunged by 5115.06% to -$80.2 million in 2025, then jumped by 99.13% to -$700000.0 in 2026.
- Business Quant data shows IOVA's Tax Provisions at -$700000.0 in Q1 2026, -$80.2 million in Q4 2025, and -$2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.40 Mn |
| Mar 31, 2026 | -700,000.00 |
| Dec 31, 2025 | -80.24 Mn |
| Sep 30, 2025 | -2.41 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | -1.84 Mn |
| Dec 31, 2024 | 1.60 Mn |
| Sep 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -1.41 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -477,000.00 |